GlobeNewsWire
02 Jun 2026, 23:40 UTC · 2h ago
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
Search tags
GlobeNewsWire
02 Jun 2026, 23:40 UTC · 2h ago
Search tags
Story key points
2 claims · impact-rated
DBV Technologies has begun screening the first participant for the THRIVE Phase 2 clinical study of the VIASKIN Peanut Patch in infants aged 6 to 12 months. — Initiating a new clinical trial phase expands the company's potential addressable market to a younger demographic, though it is an early-stage development milestone.
+0.30The THRIVE study aims to determine if the VIASKIN patch can achieve 'ad lib' dietary peanut consumption in infants through early intervention. — Proving the efficacy of 'ad lib' consumption (eating as desired) would be a significant clinical success and value driver for the product's commercial potential.
+0.20Ticker attribution
Model heads
The company has reached a positive milestone by screening the first participant in a Phase 2 clinical study for its peanut patch.
Continue reading
6 related stories
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
7h ago
